CD14 and B-cell chronic lymphocytic leukemia: Presently, there is a requirement to monitor the number of immunosuppressive CD14+HLA-DRlow/− MDSCs (>40% CD14+ monocytes) in CLL patients, as the survival time from diagnosis is currently <3 years.